Extension of the soil monitoring network via tea bag initiatives: A 3000 km latitudinal gradient in European Russia.

The increasing popularity and recognition of citizen science approaches to monitor soil health have promoted the idea to assess soil microbial decomposition based on a standard litter sample - tea bags. Although tea bag initiatives are expanding across the world, the global datasets remain biased in regard to investigating regions and biomes. This study aimed to expand the tea bag initiative to European Russia, which remains a "white spot" on the tea bag index map. We also added urban soils into the analysis, which were underestimated previously. We compared the standard and local tea brands to explore possible adaptations of the standard approach to regions with limited access to standard tea brands. The established monitoring network included natural and urban sites in six vegetation zones along a 3000 km latitudinal gradient. There was a very close linear relationship (R2 = 0.94-0.98) in the mass loss of alternative and standard tea litter. The mass loss of green tea in soil along the latitudinal gradient showed an increasing trend from north to south. Variations in the microbial decomposition of green tea were mainly explained by the latitudinal gradient, with low soil temperature identified as key factors hampering decomposition. Mass loss of the more recalcitrant rooibos tea was mainly determined via land use, with decomposition rates on average 1.3 times higher in urban soils. This pattern was in line with higher soil temperatures and pH in urban sites compared to natural counterparts. The findings of our study could prove valuable in extending the tea bag network of soil decomposition assessment into broader territories, including urban areas. Additionally, they could facilitate the involvement of citizen science and complete the database for C cycle modeling depending on climatic conditions.

[The clinical effectiveness of long-term azithromycin in patients with chronic generalized periodontitis].

The purpose of the study was to compare the clinical response to two regimes of azithromycin use in the complex of non-surgical periodontal therapy. After initial periodontal therapy of chronic generalized periodontitis (CGP), 60 patients were randomly assigned to three groups. In group I patients underwent standard medical care; In group II - patients underwent standard medical care and azithromycin: 500 mg once per day, during 3 days; In group III: 500 mg once per day, during 7 days, followed by 500 mg once per week during 12 weeks. Clinical periodontal indices were recorded before treatment and after 1, 3, 6, and 12 months. In group I after 3 months of treatment the clinical effect was lost in 65% of patients. In group III after 12 months clinical effect persisted in 80% of cases. CGP exacerbations frequency was significantly lower in group III compared with group I (χ2=8,03; р=0,0046). The long-term azithromycin at the CGP results in significantly clinical benefit of 80% patients for at least one year and satisfactorily tolerated.

[Clinical efficiency of short and long-term adjuvant therapy of chronic periodontal disease with azithromycin].

The purpose of the study was to compare the clinical response to two regimes of azithromycin use in the complex of non-surgical periodontal therapy. After initial periodontal therapy of chronic generalized periodontitis (CGP), 60 patients were randomly assigned to 3 groups. In group 2 and 3 azithromycin was administered: 500 mg 1 time per day, 3 days, and by 500 mg 1 time per day, 7 days, followed by 500 mg 1 time per week for 12 weeks. Clinical indexes were record before treatment and after 1, 3, 6 and 12 months. After 3 months 13 patients in group 1st had the exacerbation of CGP, and only 1 and 2 patients (p<0.05) in the 2nd and 3rd groups, respectively. After 12 months, significantly fewer patients on the 3rd group (as compared with the 1st (p=0.0015) and the 2nd (p=0.0040) had clinical exacerbation. Unscheduled visits were significantly less in the 3rd group as compared with the 1st (χ(2)=8.03; p=0.0046). The long-term adjunctive azithromycin results in a significantly clinical benefit of 80% patients for 1 year with satisfactory tolerance.